ELISA Kit for Anti-Synuclein Alpha Antibody (Anti-SNCa)

SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor


This assay has high sensitivity and excellent specificity for detection of Anti-Synuclein Alpha Antibody (Anti-SNCa).
No significant cross-reactivity or interference between Anti-Synuclein Alpha Antibody (Anti-SNCa) and analogues was observed.


Matrices listed below were spiked with certain level of Anti-Synuclein Alpha Antibody (Anti-SNCa) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Synuclein Alpha Antibody (Anti-SNCa) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-103 93
EDTA plasma(n=5) 99-105 102
heparin plasma(n=5) 90-97 94


Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Synuclein Alpha Antibody (Anti-SNCa) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Synuclein Alpha Antibody (Anti-SNCa) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%


The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Synuclein Alpha Antibody (Anti-SNCa) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 90-97% 89-96% 96-103% 98-105%
EDTA plasma(n=5) 79-103% 80-90% 88-101% 83-99%
heparin plasma(n=5) 82-89% 82-91% 86-95% 80-89%


The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.



Magazine Citations
The Journal of Clinical Investigation Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration PubMed: PMC3428100
Neurobiology of Disease Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission PubMed: PMC3107939
Nature Communications Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus PubMed: PMC3265381
Provisional chapter Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease Intechopen:Source
Nerodegeneration Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment pubmed:29326545
Experimental gerontology The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. pubmed:29107062
Neurobiology of Disease Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity Pubmed: 30521842
molecular and cellular biochemistry Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model Pubmed: 31820278
International Journal of Pharmacology Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease Pubmed: 32084576
EBioMedicine Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys Pubmed: 32810825
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB222Hu01 Recombinant Synuclein Alpha (SNCa) Positive Control; Immunogen; SDS-PAGE; WB.
PAB222Hu01 Polyclonal Antibody to Synuclein Alpha (SNCa) WB; IHC; ICC; IP.
LAB222Hu71 Biotin-Linked Polyclonal Antibody to Synuclein Alpha (SNCa) WB; IHC; ICC.
MAB222Hu22 Monoclonal Antibody to Synuclein Alpha (SNCa) WB; IHC; ICC; IP.
SEB222Hu ELISA Kit for Synuclein Alpha (SNCa) Enzyme-linked immunosorbent assay for Antigen Detection.
AEB222Hu ELISA Kit for Anti-Synuclein Alpha Antibody (Anti-SNCa) Enzyme-linked immunosorbent assay for Antibody Detection.